{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T13:23:18Z","timestamp":1772025798498,"version":"3.50.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T00:00:00Z","timestamp":1501113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T00:00:00Z","timestamp":1501113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013945","name":"Institut de Recherches Internationales Servier","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013945","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The apolipoprotein E \u03b54 (\n                      <jats:italic>APO<\/jats:italic>\n                      E4) genotype is a prominent late-onset Alzheimer\u2019s disease (AD) risk factor. ApoE4 disrupts memory function in rodents and may contribute to both plaque and tangle formation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Coimmunoprecipitation and Western blot detection were used to determine: 1) the effects of select fragments from the apoE low-density lipoprotein (LDL) binding domain and recombinant apoE subtypes on amyloid beta (A\u03b2)\n                      <jats:sub>42<\/jats:sub>\n                      -\u03b17 nicotinic acetylcholine receptor (\u03b17nAChR) interaction and tau phosphorylation in rodent brain synaptosomes; and 2) the level of A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      -\u03b17nAChR complexes in matched controls and patients with mild cognitive impairment (MCI) and dementia due to AD with known\n                      <jats:italic>APO<\/jats:italic>\n                      E genotypes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In an ex vivo study using rodent synaptosomes, apoE\n                      <jats:sub>141\u2013148<\/jats:sub>\n                      of the apoE promotes A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      -\u03b17nAChR association and A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      -induced \u03b17nAChR-dependent tau phosphorylation. In a single-blind study, we examined lymphocytes isolated from control subjects, patients with MCI and dementia due to AD with known\n                      <jats:italic>APO<\/jats:italic>\n                      E genotypes, sampled at two time points (1\u00a0year apart).\n                      <jats:italic>APO<\/jats:italic>\n                      E \u03b54 genotype was closely correlated with heightened A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      -\u03b17nAChR complex levels and with blunted exogenous A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      effects in lymphocytes derived from AD and MCI due to AD cases. Similarly, plasma from\n                      <jats:italic>APO<\/jats:italic>\n                      E \u03b54 carriers enhanced the A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      -induced A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      -\u03b17nAChR association in rat cortical synaptosomes. The progression of cognitive decline in\n                      <jats:italic>APO<\/jats:italic>\n                      E \u03b54 carriers correlated with higher levels of A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      -\u03b17nAChR complexes in lymphocytes and greater enhancement by their plasma of A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      -induced A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      -\u03b17nAChR association in rat cortical synaptosomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our data suggest that increased lymphocyte A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      -\u03b17nAChR-like complexes may indicate the presence of AD pathology especially in\n                      <jats:italic>APO<\/jats:italic>\n                      E \u03b54 carriers. We show that apoE, especially apoE4, promotes A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      -\u03b17nAChR interaction and A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      -induced \u03b17nAChR-dependent tau phosphorylation via its apoE\n                      <jats:sub>141\u2013148<\/jats:sub>\n                      domain\n                      <jats:sub>.<\/jats:sub>\n                      These apoE-mediated effects may contribute to the\n                      <jats:italic>APO<\/jats:italic>\n                      E \u03b54-driven neurodysfunction and AD pathologies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-017-0280-8","type":"journal-article","created":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T07:17:32Z","timestamp":1501139852000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["RETRACTED ARTICLE: Increased A\u03b242-\u03b17-like nicotinic acetylcholine receptor complex level in lymphocytes is associated with apolipoprotein E4-driven Alzheimer\u2019s disease pathogenesis"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5005-7564","authenticated-orcid":false,"given":"Hoau-Yan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caryn","family":"Trocm\u00e9-Thibierge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Stucky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanket M.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Kvasic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Morain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Guignot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Bouguen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Deschet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Pueyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Mocaer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Jean","family":"Ousset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Vellas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Kiyasova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,27]]},"reference":[{"key":"280_CR1","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M","volume":"46","author":"CA McLean","year":"1999","unstructured":"McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of A\u03b2 amyloid as a determinant of severity of neurodegeneration in Alzheimer\u2019s disease. Ann Neurol. 1999;46:860\u20136.","journal-title":"Ann Neurol."},{"key":"280_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0306-4522(01)00460-2","volume":"110","author":"RG Nagele","year":"2002","unstructured":"Nagele RG, D\u2019Andrea MR, Anderson WJ, Wang HY. Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer\u2019s disease. Neuroscience. 2002;110:199\u2013211.","journal-title":"Neuroscience."},{"key":"280_CR3","doi-asserted-by":"publisher","first-page":"31547","DOI":"10.1074\/jbc.M212532200","volume":"278","author":"HY Wang","year":"2003","unstructured":"Wang HY, Li W, Benedetti N, Lee DHS. \u03b17 Nicotinic acetylcholine receptors mediate \u03b2-amyloid peptides-induced tau protein phosphorylation. J Biol Chem. 2003;278:31547\u201353.","journal-title":"J Biol Chem."},{"key":"280_CR4","doi-asserted-by":"publisher","first-page":"10961","DOI":"10.1523\/JNEUROSCI.6088-08.2009","volume":"29","author":"HY Wang","year":"2009","unstructured":"Wang HY, Stucky A, Liu J, Shen C, Trocm\u00e9-Thibierge C, Morain P. Dissociating \u03b2-amyloid from \u03b17 nicotinic acetylcholine receptor by a novel therapeutic agent, S 24795, normalizes \u03b17 nicotinic acetylcholine and NMDA receptor function in Alzheimer\u2019s disease brain. J Neurosci. 2009;29:10961\u201373.","journal-title":"J Neurosci."},{"key":"280_CR5","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.biopsych.2009.09.031","volume":"67","author":"HY Wang","year":"2010","unstructured":"Wang HY, Bakshi K, Shen C, Frankfurt M, Trocm\u00e9-Thibierge C, Morain P. S 24795 limits \u03b2-amyloid-\u03b17 nicotinic receptor interaction and reduces Alzheimer\u2019s disease-like pathologies. Biol Psychiatry. 2010;67:522\u201330.","journal-title":"Biol Psychiatry."},{"key":"280_CR6","doi-asserted-by":"publisher","first-page":"8805","DOI":"10.1523\/JNEUROSCI.6159-08.2009","volume":"29","author":"G Dziewczapolski","year":"2009","unstructured":"Dziewczapolski G, Glogowski CM, Masliah E, Heinemann SF. Deletion of the \u03b17 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer\u2019s disease. J Neurosci. 2009;29:8805\u201315.","journal-title":"J Neurosci."},{"issue":"29","key":"280_CR7","doi-asserted-by":"publisher","first-page":"9773","DOI":"10.1523\/JNEUROSCI.0354-12.2012","volume":"32","author":"HY Wang","year":"2012","unstructured":"Wang HY, Bakshi K, Frankfurt M, Stucky A, Goberdhan M, Shah SM, et al. Reducing amyloid-related Alzheimer\u2019s disease pathogenesis by a small molecule targeting filamin A. J Neurosci. 2012;32(29):9773\u201384.","journal-title":"J Neurosci"},{"key":"280_CR8","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","volume":"278","author":"LA Farrer","year":"1997","unstructured":"Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA. 1997;278:1349\u201356.","journal-title":"JAMA."},{"key":"280_CR9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.molmed.2010.04.004","volume":"16","author":"Y Huang","year":"2010","unstructured":"Huang Y. A\u03b2-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer\u2019s disease. Trends Mol Med. 2010;16:287\u201394.","journal-title":"Trends Mol Med."},{"key":"280_CR10","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.cell.2012.02.040","volume":"148","author":"Y Huang","year":"2012","unstructured":"Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148:1204\u201322.","journal-title":"Cell."},{"key":"280_CR11","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1097\/00001756-199611040-00025","volume":"7","author":"MA Marques","year":"1996","unstructured":"Marques MA, Tolar M, Harmony JA, Crutcher KA. A thrombin cleavage fragment of apolipoprotein E exhibits isoform-specific neurotoxicity. Neuroreport. 1996;7:2529\u201332.","journal-title":"Neuroreport."},{"key":"280_CR12","doi-asserted-by":"publisher","first-page":"11142","DOI":"10.1021\/bi00035a020","volume":"34","author":"MA Clay","year":"1995","unstructured":"Clay MA, Anantharamaiah GM, Mistry MJ, Balasubramaniam A, Harmony JA. Localization of a domain in apolipoprotein E with both cytostatic and cytotoxic activity. Biochemistry. 1995;34:11142\u201351.","journal-title":"Biochemistry."},{"key":"280_CR13","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.1523\/JNEUROSCI.17-15-05678.1997","volume":"17","author":"M Tolar","year":"1997","unstructured":"Tolar M, Marques MA, Harmony JA, Crutcher KA. Neurotoxicity of the 22\u00a0kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated. J Neurosci. 1997;17:5678\u201386.","journal-title":"J Neurosci."},{"key":"280_CR14","doi-asserted-by":"publisher","first-page":"9649","DOI":"10.1073\/pnas.90.20.9649","volume":"90","author":"DE Schmechel","year":"1993","unstructured":"Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, et al. Increased amyloid \u03b2-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:9649\u201353.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"280_CR15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/372092a0","volume":"372","author":"J Ma","year":"1994","unstructured":"Ma J, Yee A, Brewer Jr HB, Das S, Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature. 1994;372:92\u20134.","journal-title":"Nature."},{"key":"280_CR16","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8","volume":"47","author":"DM Holtzman","year":"2000","unstructured":"Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer\u2019s disease model. Ann Neurol. 2000;47:739\u201347.","journal-title":"Ann Neurol."},{"key":"280_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s004010000263","volume":"100","author":"MC Irizarry","year":"2000","unstructured":"Irizarry MC, Cheung BS, Rebeck GW, Paul SM, Bales KR, Hyman BT. Apolipoprotein E affects the amount, form, and anatomical distribution of amyloid beta-peptide deposition in homozygous APP(V717F) transgenic mice. Acta Neuropathol. 2000;100:451\u20138.","journal-title":"Acta Neuropathol."},{"key":"280_CR18","doi-asserted-by":"publisher","first-page":"959","DOI":"10.3233\/JAD-2010-101008","volume":"22","author":"H Belinson","year":"2010","unstructured":"Belinson H, Kariv-Inbal Z, Kayed R, Masliah E, Michaelson DM. Following activation of the amyloid cascade, apolipoprotein E4 drives the in vivo oligomerization of amyloid-\u03b2 resulting in neurodegeneration. J Alzheimers Dis. 2010;22:959\u201370.","journal-title":"J Alzheimers Dis."},{"key":"280_CR19","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/792070","author":"L Zepa","year":"2011","unstructured":"Zepa L, Frenkel M, Belinson H, Kariv-Inbal Z, Kayed R, Masliah E, et al. ApoE4-driven accumulation of intraneuronal oligomerized A\u03b242 following activation of the amyloid cascade in vivo is mediated by a gain of function. Int J Alzheimers Dis. 2011. doi:10.4061\/2011\/792070.","journal-title":"Int J Alzheimers Dis"},{"key":"280_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/ng0996-55","volume":"14","author":"M Miyata","year":"1996","unstructured":"Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet. 1996;14:55\u201361.","journal-title":"Nat Genet."},{"key":"280_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/35036221","volume":"1","author":"J Herz","year":"2000","unstructured":"Herz J, Beffert U. Apolipoprotein E receptors: linking brain development and Alzheimer\u2019s disease. Nat Rev Neurosci. 2000;1:51\u20138.","journal-title":"Nat Rev Neurosci."},{"key":"280_CR22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/jnr.10138","volume":"67","author":"I Veinbergs","year":"2002","unstructured":"Veinbergs I, Everson A, Sagara Y, Masliah E. Neurotoxic effects of apolipoprotein E4 are mediated via dysregulation of calcium homeostasis. J Neurosci Res. 2002;67:379\u201387.","journal-title":"J Neurosci Res."},{"key":"280_CR23","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.8171342","volume":"264","author":"BP Nathan","year":"1994","unstructured":"Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science. 1994;264:850\u20132.","journal-title":"Science."},{"key":"280_CR24","doi-asserted-by":"publisher","first-page":"19791","DOI":"10.1074\/jbc.270.34.19791","volume":"270","author":"BP Nathan","year":"1995","unstructured":"Nathan BP, Chang KC, Bellosta S, Brisch E, Ge N, Mahley RW, et al. The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization. J Biol Chem. 1995;270:19791\u20139.","journal-title":"J Biol Chem."},{"key":"280_CR25","doi-asserted-by":"crossref","unstructured":"Strittmatter WJ, Saunders AM, Goedert M, Weisgraber KH, Dong LM, Jakes R, et al. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci USA. 1994;91:11183\u20136.","DOI":"10.1073\/pnas.91.23.11183"},{"key":"280_CR26","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0002-9440(10)64963-2","volume":"156","author":"I Tesseur","year":"2000","unstructured":"Tesseur I, Van Dorpe J, Bruynseels K, Bronfman F, Sciot R, Van Lommel A, et al. Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am J Pathol. 2000;156:951\u201364.","journal-title":"Am J Pathol."},{"key":"280_CR27","doi-asserted-by":"publisher","first-page":"8838","DOI":"10.1073\/pnas.151254698","volume":"98","author":"Y Huang","year":"2001","unstructured":"Huang Y, Liu XQ, Wyss-Coray T, Brecht WJ, Sanan DA, Mahley RW. Apolipoprotein E fragments present in Alzheimer\u2019s disease brains induced neurofibrillary tangles-like intracellular inclusions in neurons. Proc Natl Acad Sci U S A. 2001;98:8838\u201343.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"280_CR28","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1097\/00001756-200205070-00026","volume":"13","author":"MC Ljungberg","year":"2002","unstructured":"Ljungberg MC, Dayanandan R, Asuni A, Rupniak TH, Anderton BH, Lovestone S. Truncated apoE forms tangle-like structures in a neuronal cell line. Neuroreport. 2002;13:867\u201370.","journal-title":"Neuroreport."},{"key":"280_CR29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.neuroscience.2004.05.045","volume":"127","author":"RC Klein","year":"2004","unstructured":"Klein RC, Yakel JL. Inhibition of nicotinic acetylcholine receptors by apolipoprotein E-derived peptides in rat hippocampal slices. Neuroscience. 2004;127:563\u20137.","journal-title":"Neuroscience."},{"key":"280_CR30","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1124\/jpet.105.095505","volume":"316","author":"EA Gay","year":"2006","unstructured":"Gay EA, Klein RC, Yakel JL. Apolioprotein E-derived peptide block \u03b17 neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Pharmacol Exp Ther. 2006;316:835\u201342.","journal-title":"J Pharmacol Exp Ther."},{"key":"280_CR31","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1124\/mol.107.035527","volume":"72","author":"EA Gay","year":"2007","unstructured":"Gay EA, Bienstock RJ, Lamb PW, Yakel JL. Structural determinates for apolipoprotein E-derived peptide interaction with the \u03b17 neuronal nicotinic acetylcholine receptor. Mol Pharmacol. 2007;72:838\u201349.","journal-title":"Mol Pharmacol."},{"key":"280_CR32","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.1074\/jbc.275.8.5626","volume":"275","author":"HY Wang","year":"2000","unstructured":"Wang HY, Lee DH, D\u2019Andrea MR, Peterson PA, Shank RP, Reitz AB. \u03b2-amyloid1\u201342 binds to \u03b17 nicotinic acetylcholine receptor with high affinity: implications for Alzheimer\u2019s disease pathology. J Biol Chem. 2000;275:5626\u201332.","journal-title":"J Biol Chem"},{"key":"280_CR33","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1046\/j.1471-4159.2000.0751155.x","volume":"75","author":"HY Wang","year":"2000","unstructured":"Wang HY, Lee DH, Davie CB, Shank RP. Amyloid peptide A\u03b21\u201342 binds selectively and with picomolar affinity to 7 nicotinic acetylcholine receptors. J Neurochem. 2000;75:1155\u201361.","journal-title":"J Neurochem."},{"key":"280_CR34","doi-asserted-by":"publisher","unstructured":"de Mauleon A, Kiyasova V, Delrieu J, Vellas B, Guignot I, Galtier S, et al. The ROSAS cohort: a prospective, longitudinal study of biomarkers for Alzheimer\u2019s disease. Strategy, methods and initial results. J Prev Alzheimers Dis. 2017. doi.10.14283\/jpad2017.8.","DOI":"10.14283\/jpad2017.8"},{"key":"280_CR35","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.bcp.2011.06.018","volume":"82","author":"T Araud","year":"2011","unstructured":"Araud T, Graw S, Berger R, Lee M, Neveu E, Bertrand D, et al. The chimeric gene CHRFAM7A, a partial duplication of the CHRNA7 gene, is a dominant negative regulator of \u03b17-nAChR function. Biochem Pharmacol. 2011;82:904\u201314.","journal-title":"Biochem Pharmacol."},{"key":"280_CR36","doi-asserted-by":"publisher","first-page":"10966","DOI":"10.1073\/pnas.1434398100","volume":"100","author":"FM Harris","year":"2003","unstructured":"Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekonius L, Wyss-Coray T, et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer\u2019s disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci U S A. 2003;100:10966\u201371.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"280_CR37","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1523\/JNEUROSCI.4315-03.2004","volume":"24","author":"WJ Brecht","year":"2004","unstructured":"Brecht WJ, Harris FM, Chang S, Tesseur I, Yu GQ, Xu Q, et al. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci. 2004;24:2527\u201334.","journal-title":"J Neurosci."},{"key":"280_CR38","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.neuron.2012.11.020","volume":"76","author":"RW Mahley","year":"2012","unstructured":"Mahley RW, Huang Y. Apolipoprotein E4 sets the stage: response to injury triggers neuropathology. Neuron. 2012;76:871\u201385.","journal-title":"Neuron."},{"key":"280_CR39","doi-asserted-by":"publisher","first-page":"18694","DOI":"10.1073\/pnas.0508254102","volume":"102","author":"S Chang","year":"2005","unstructured":"Chang S, ran Ma T, Miranda RD, Balestra ME, Mahley RW, Huang Y. Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc Natl Acad Sci U S A. 2005;102:18694\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"280_CR40","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science. 1993;261:921\u20133.","journal-title":"Science."},{"key":"280_CR41","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/0896-6273(93)90070-8","volume":"11","author":"GW Rebeck","year":"1993","unstructured":"Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer\u2019s disease: allele variation and receptor interactions. Neuron. 1993;11:575\u201380.","journal-title":"Neuron."},{"issue":"4","key":"280_CR42","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.neurobiolaging.2010.05.017","volume":"33","author":"MA Beydoun","year":"2012","unstructured":"Beydoun MA, Boueiz A, Abougergi MS, Kitner-Triolo MH, Beydoun HA, Resnick SM, et al. Sex differences in the association of the apolipoprotein E epsilon 4 allele with incidence of dementia, cognitive impairment, and decline. Neurobiol Aging. 2012;33(4):720\u201331.","journal-title":"Neurobiol Aging"},{"issue":"24","key":"280_CR43","doi-asserted-by":"publisher","first-page":"8254","DOI":"10.1523\/JNEUROSCI.0305-12.2012","volume":"32","author":"JS Damoiseaux","year":"2012","unstructured":"Damoiseaux JS, Seeley WW, Zhou J, Shirer WR, Coppola G, Karydas A, et al. Alzheimer\u2019s Disease Neuroimaging I. Gender modulates the APOE epsilon4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. J Neurosci. 2012;32(24):8254\u201362.","journal-title":"J Neurosci"},{"issue":"12","key":"280_CR44","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.3174\/ajnr.A3601","volume":"34","author":"D Holland","year":"2013","unstructured":"Holland D, Desikan RS, Dale AM, McEvoy LK. Alzheimer\u2019s Disease Neuroimaging I. Higher rates of decline for women and apolipoprotein E epsilon4 carriers. AJNR Am J Neuroradiol. 2013;34(12):2287\u201393.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"4","key":"280_CR45","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/ana.24135","volume":"75","author":"A Altmann","year":"2014","unstructured":"Altmann A, Tian L, Henderson VW, Greicius MD. Alzheimer\u2019s Disease Neuroimaging Initiative I. Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol. 2014;75(4):563\u201373.","journal-title":"Ann Neurol"},{"key":"280_CR46","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1126\/scitranslmed.3004274","volume":"4","author":"S Gandy","year":"2012","unstructured":"Gandy S, Dekosky ST. APOE \u03b54 status and traumatic brain injury on the gridiron or on the battlefield. Sci Transl Med. 2012;4:134.","journal-title":"Sci Transl Med."},{"key":"280_CR47","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1212\/WNL.57.5.853","volume":"57","author":"F Fazekas","year":"2001","unstructured":"Fazekas F, Strasser-Fuchs S, Kollegger H, Berger T, Kristoferitsch W, Schmidt H, et al. Apolipoprotein E \u03b54 is associated with rapid progression of multiple sclerosis. Neurology. 2001;57:853\u20137.","journal-title":"Neurology."},{"key":"280_CR48","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1212\/WNL.54.6.1272","volume":"54","author":"BS Harhangi","year":"2000","unstructured":"Harhangi BS, de Rijk MC, van Duijn CM, Van Broeckhoven C, Hofman A, Breteler MMB. APOE and the risk of PD with or without dementia in a population-based study. Neurology. 2000;54:1272\u20136.","journal-title":"Neurology."},{"key":"280_CR49","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1073\/pnas.0812697106","volume":"106","author":"F Agosta","year":"2009","unstructured":"Agosta F, Vossel KA, Miller BL, Migliaccio R, Bonasera SJ, Filippi M, et al. Apolipoprotein E \u03b54 is associated with disease-specific effects on brain atrophy in Alzheimer\u2019s disease and frontotemporal dementia. Proc Natl Acad Sci U S A. 2009;106:2018\u201322.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"280_CR50","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0140-6736(95)91411-0","volume":"345","author":"MJ Aberts","year":"1995","unstructured":"Aberts MJ, Graffragnino C, McClenny C, DeLong D, Strittmatter W, Saunders AM, et al. ApoE geneotype and survival from intracerebral haemorrhage. Lancet. 1995;345:575.","journal-title":"Lancet."},{"key":"280_CR51","doi-asserted-by":"publisher","first-page":"8913","DOI":"10.1073\/pnas.1207022109","volume":"109","author":"C Frieden","year":"2012","unstructured":"Frieden C, Garai K. Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2012;109:8913\u20138.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"280_CR52","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/ng1197-263","volume":"17","author":"KR Bales","year":"1997","unstructured":"Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 1997;17:263\u20134.","journal-title":"Nat Genet."},{"key":"280_CR53","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0006-8993(91)91092-F","volume":"541","author":"Y Namba","year":"1991","unstructured":"Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer\u2019s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991;541:163\u20136.","journal-title":"Brain Res."},{"key":"280_CR54","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1056\/NEJM199511093331902","volume":"333","author":"T Polvikoski","year":"1995","unstructured":"Polvikoski T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkkoniemi A, et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med. 1995;333:1242\u20137.","journal-title":"N Engl J Med."},{"key":"280_CR55","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/ana.21696","volume":"65","author":"E Kok","year":"2009","unstructured":"Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S, Haapasalo H, et al. Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol. 2009;65:650\u20137.","journal-title":"Ann Neurol."},{"key":"280_CR56","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","volume":"10","author":"H Barthel","year":"2011","unstructured":"Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-\u03b2 PET with florbetaben (18\u00a0F) in patients with Alzheimer\u2019s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424\u201335.","journal-title":"Lancet Neurol."},{"key":"280_CR57","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.1073\/pnas.0900345106","volume":"106","author":"EM Reiman","year":"2009","unstructured":"Reiman EM. Fibrillar amyloid-\u03b2 burden in cognitively normal people at 3 levels of genetic risk for Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2009;106:6820\u20135.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"10","key":"280_CR58","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaneurol.2015.1721","volume":"72","author":"SE Monsell","year":"2015","unstructured":"Monsell SE, Kukull WA, Roher AE, Maarouf CL, Serrano G, Beach TG, et al. Characterizing apolipoprotein E \u03b54 carriers and noncarriers with the clinical diagnosis of mild to moderate Alzheimer dementia and minimal \u03b2-amyloid peptide plaques. JAMA Neurol. 2015;72(10):1124\u201331.","journal-title":"JAMA Neurol"},{"key":"280_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2012.04.017","volume":"34","author":"AS Fleisher","year":"2013","unstructured":"Fleisher AS, Chen K, Liu X, Ayutyanont N, Roontiva A, Thiyyagura P, et al. Apolipoprotein E \u03b54 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging. 2013;34:1\u201312.","journal-title":"Neurobiol Aging."},{"key":"280_CR60","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1212\/01.wnl.0000343853.00346.a4","volume":"72","author":"DJ Berlau","year":"2009","unstructured":"Berlau DJ, Corrada MM, Head E, Kawas CH. APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology. 2009;72:829\u201334.","journal-title":"Neurology."},{"key":"280_CR61","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1161\/01.STR.0000064320.73388.C6","volume":"34","author":"K Aoki","year":"2003","unstructured":"Aoki K, Uchihara T, Sanjo N, Nakamura A, Ikeda K, Tsuchiya K, et al. Increased expression of neuronal apolipoprotein E in human brain with cerebral infarction. Stroke. 2003;34:875\u201380.","journal-title":"Stroke."},{"key":"280_CR62","doi-asserted-by":"publisher","first-page":"5644","DOI":"10.1073\/pnas.0600549103","volume":"103","author":"RW Mahley","year":"2006","unstructured":"Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2006;103:5644\u201351.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"280_CR63","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1741-7015-10-35","volume":"10","author":"O Aboud","year":"2012","unstructured":"Aboud O, Mrak RE, Boop F, Griffin ST. Apolipoprotein epsilon 3 alleles are associated with indicators of neuronal resilience. BMC Med. 2012;10:35.","journal-title":"BMC Med."},{"key":"280_CR64","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2353\/ajpath.2010.090973","volume":"177","author":"M Buttini","year":"2010","unstructured":"Buttini M, Masliah E, Yu GQ, Palop JJ, Chang S, Bernardo A, et al. Cellular source of apolipoprotein E4 determines neuronal susceptibility to excitotoxic injury in transgenic mice. Am J Pathol. 2010;177:563\u20139.","journal-title":"Am J Pathol."},{"key":"280_CR65","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jneuroim.2005.09.011","volume":"217","author":"M Skok","year":"2006","unstructured":"Skok M, Grailhe R, Agenes F, Changeux J-P. The role of nicotinic acetylcholine receptors in lymphocyte development. J Neuroimmunol. 2006;217:86\u201398.","journal-title":"J Neuroimmunol."},{"key":"280_CR66","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.lfs.2009.07.010","volume":"85","author":"MJ De Rosa","year":"2009","unstructured":"De Rosa MJ, Dionisio L, Agriello E, Bouzat C, del Esandi MC. Alpha7 nicotinic acetylcholine receptor modulates lymphocyte activation. Life Sci. 2009;85:444\u20139.","journal-title":"Life Sci."},{"key":"280_CR67","first-page":"5","volume":"81","author":"LM Koval","year":"2009","unstructured":"Koval LM, Yu Lykhmus O, Omelchenko DM, Komisarenko SV, Skok MV. The role of alpha7 nicotinic acetylcholine receptors in B lymphocyte activation. Ukr Biokhim Zh. 2009;81:5\u201311.","journal-title":"Ukr Biokhim Zh."},{"key":"280_CR68","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000082661","volume":"19","author":"LW Chu","year":"2005","unstructured":"Chu LW, Ma ES, Lam KK, Chan MF, Lee DH. Increased alpha 7 nicotinic acetylcholine receptor protein levels in Alzheimer\u2019s disease patients. Dement Geriatr Cogn Disord. 2005;19:106\u201312.","journal-title":"Dement Geriatr Cogn Disord."},{"issue":"Suppl 1\u20132","key":"280_CR69","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1385\/JMN:30:1:83","volume":"30","author":"IW Jones","year":"2006","unstructured":"Jones IW, Westmacott A, Chan E, Jones RW, Dineley K, O\u2019Neill MJ, et al. \u03b17 nicotinic acetylcholine receptor expression in Alzheimer\u2019s disease. J Mol Neurosci. 2006;30(Suppl 1\u20132):83\u20134.","journal-title":"J Mol Neurosci"},{"key":"280_CR70","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nm.3466","volume":"20","author":"M Mapstone","year":"2014","unstructured":"Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med. 2014;20:415\u20138.","journal-title":"Nat Med."},{"key":"280_CR71","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1084\/jem.20091419","volume":"207","author":"NC Derecki","year":"2010","unstructured":"Derecki NC, Cardani AN, Yang CH, Quinnies KM, Crihfield A, Lynch KR, et al. Regulation of learning and memory by meningeal immunity: a key role for IL-4. J Exp Med. 2010;207:1067\u201380.","journal-title":"J Exp Med."},{"key":"280_CR72","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.bbi.2010.10.015","volume":"25","author":"R Yirmiya","year":"2011","unstructured":"Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun. 2011;25:181\u2013213.","journal-title":"Brain Behav Immun."},{"key":"280_CR73","doi-asserted-by":"publisher","first-page":"11044","DOI":"10.1523\/JNEUROSCI.2125-11.2011","volume":"31","author":"HY Wang","year":"2011","unstructured":"Wang HY, Crupi D, Liu J, Stucky A, Cruciata G, Di Rocco A, et al. rTMS enhances BDNF-TrkB signaling in both brain and lymphocytes. J Neurosci. 2011;31:11044\u201354.","journal-title":"J Neurosci."},{"key":"280_CR74","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/0024-3205(86)90506-0","volume":"39","author":"H Lal","year":"1986","unstructured":"Lal H, Bennett M, Bennett D, Forster MJ, Nandy K. Learning deficits occur in young mice following transfer of immunity from senescent mice. Life Sci. 1986;39:507\u201312.","journal-title":"Life Sci."},{"key":"280_CR75","doi-asserted-by":"publisher","first-page":"e23112","DOI":"10.1371\/journal.pone.0023112","volume":"6","author":"E Nagele","year":"2011","unstructured":"Nagele E, Han M, Demarshall C, Belinka B, Nagele R. Diagnosis of Alzheimer\u2019s disease based on disease-specific autoantibody profiles in human sera. PLoS One. 2011;6:e23112.","journal-title":"PLoS One."},{"key":"280_CR76","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1586\/ern.09.118","volume":"9","author":"K Rezai-Zadeh","year":"2009","unstructured":"Rezai-Zadeh K, Gate D, Szekely CA, Town T. Can peripheral leukocytes be used as Alzheimer\u2019s disease biomarkers? Expert Rev Neurother. 2009;9:1623\u201333.","journal-title":"Expert Rev Neurother."},{"key":"280_CR77","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.1523\/JNEUROSCI.0033-12.2012","volume":"32","author":"N Bien-Ly","year":"2012","unstructured":"Bien-Ly N, Gillespie AK, Walker D, Yoon SY, Huang Y. Reducing human apolipoprotein E levels attenuates age-dependent Abeta accumulation in mutant human amyloid precursor protein transgenic mice. J Neurosci. 2012;32:4803\u201311.","journal-title":"J Neurosci."},{"key":"280_CR78","doi-asserted-by":"publisher","first-page":"18787","DOI":"10.1073\/pnas.0604011103","volume":"103","author":"MJ Sadowski","year":"2006","unstructured":"Sadowski MJ, Pankiewicz J, Scholtzova H, Mehta PD, Prelli F, Quartermain D, et al. Blocking the apolipoprotein E\/amyloid-beta interaction as a potential therapeutic approach for Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2006;103:18787\u201392.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"280_CR79","doi-asserted-by":"crossref","unstructured":"Wang HY, Lee K-C, Pei Z, Khan A, Bakshi K, Burns LH. PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer's disease pathogenesis. Neurobiol Aging. 2017 in press.","DOI":"10.1016\/j.neurobiolaging.2017.03.016"}],"updated-by":[{"DOI":"10.1186\/s13195-022-01024-5","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"record-id":"37456"},{"DOI":"10.1186\/s13195-017-0280-8","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000}},{"DOI":"10.1186\/s13195-022-01024-5","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000}}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-017-0280-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-017-0280-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-017-0280-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:05:02Z","timestamp":1772021102000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-017-0280-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,27]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["280"],"URL":"https:\/\/doi.org\/10.1186\/s13195-017-0280-8","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,27]]},"assertion":[{"value":"10 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Editor's Note: Readers are alerted that the reliability of the western blot data reported in this article is currently under dispute. The Editorial team is currently investigating these concerns. Further editorial action will be taken as appropriate once the investigation into the concerns is complete and all parties have been given an opportunity to respond in full.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13195-022-01024-5","URL":"https:\/\/doi.org\/10.1186\/s13195-022-01024-5","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal procedures comply with the National Institutes of Health Guide for Care Use of Laboratory Animals and were approved by the City College of New York Animal Care and Use Committee (IACUC) Protocol no. 836.1. Human participants and their informed caregiver took part in the study on a voluntary basis, and they gave their written informed consent at selection. The ethics committee of Toulouse University Hospital approved the study protocol and all its amendments (registration number DGS 20060500).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"H-YW received grants from, and is a consultant of, the Institut De Recherche SERVIER. CT-T, IG, EB, KD, MP, EM, and VKva are employees of the Institut De Recherche SERVIER. The remaining authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"54"}}